期刊文献+

临床药师参与治疗2例多重耐药肺炎链球菌脑膜炎患儿实践体会 被引量:2

Pharmaceutical Practice for Two Children with Multi-Drug Resistant Streptococcus Pneumoniae Meningitis by Clinical Pharmacists
下载PDF
导出
摘要 目的:探讨临床药师在多重耐药肺炎链球菌脑膜炎患儿抗感染治疗中的作用。方法:临床药师参与2例多重耐药肺炎链球菌脑膜炎患儿的治疗过程。2例患儿根据药敏结果选择万古霉素作为主要抗感染药物,感染指标未下降,病情恶化。临床药师分析了万古霉素治疗效果不佳的原因,建议医师换用利奈唑胺,并对利奈唑胺在儿童细菌性脑膜炎中的应用进行了分析。结果:2例患儿在使用利奈唑胺治疗2周后,感染得到控制,好转出院。结论:临床药师参与抗感染方案制定,可以为医师提供参考,最终使患者获益。 Objective:To explore the role of clinical pharmacists in the anti-infection treatment for children with multi-drug resistant Streptococcus pneumoniae meningitis.Methods:Clinical pharmacists participated into the treatment process of two children with multidrug resistant S.pneumoniae meningitis.Vancomycin was selected as the main anti-infection drug according to the drug sensitivity results.The infection index did not decrease and the condition deteriorated.The clinical pharmacists analyzed the reasons for the poor efficacy of vancomycin treatment,suggested the clinicians to use linezolid,and analyzed the application of linezolid in multi-drug resistant S.pneumoniae meningitis in children.Results:After two weeks of treatment with inezolid,the infection was controlled and the patients were discharged from the hospital.Conclusion:The involvement of clinical pharmacists in the formulation of anti-infection programs can provide reference for clinicians and ultimately benefit the patients.
作者 温晓漪 仇锦春 Wen Xiaoyi;Qiu Jinchun(Children’s Hospital of Nanjing Medical University,Jiangsu Nanjing 210000,China)
出处 《儿科药学杂志》 CAS 2019年第10期33-37,共5页 Journal of Pediatric Pharmacy
关键词 利奈唑胺 万古霉素 多重耐药肺炎链球菌 脑膜炎 linezolid vancomycin multi-drug resistant Streptococcus pneumonia meningitis
  • 相关文献

参考文献10

二级参考文献94

  • 1朱曼,郭代红,石莉,宁静,裴保香.2000-2004年我院4种抗癫痫药物血药浓度监测结果分析[J].药物流行病学杂志,2005,14(4):223-225. 被引量:3
  • 2汪复,张婴元.实用抗感染治疗学[M].北京:人民卫生出版社,2005:134.
  • 3Boh LE.药学临床实践指南[M].陆进,常明,译.北京:化学工业出版社,2007:223-224.
  • 4Jesus Valle M J, Lopez FG, Navarro AS. Development and validation of an HPLC method for vancomyein and its application to a pharmacokinetic study[J]. J Pharm Biomed Anal, 2008, 48(3): 835-839.
  • 5Lee P, Dipersio D, Jerome RN, et al. Approaching and analyzing a large literature on vancomycin monitoring and pharmacokinetics[J]: J Med Libr Assoc, 2007, 95(4): 374-380.
  • 6Nakayama H, Echizen H, Tanaka M, et al. Reduced vancomycin clearance despite unchanged creatinine clearance in patients treated with vancomycin for longer than 4 weeks[J]. Ther Drug Monit, 2008, 30(1): 103-107.
  • 7Ramphal R. Importance of adequate initial antimicrobial therapy[J]. Chemotherapy, 2005, 51(4): 171-176.
  • 8Iwamoto T, Kagawa Y, Kojima M. Clinical efficacy of therapeutic drug monitoring in patients receiving vancomycin[J]. Biol Pharm Bull, 2003, 26(6): 876-879.
  • 9Rybak M J, Albrecht LM, Boike SC, et al. Nephrotoxicity of vancomycin, alone and with an aminoglycoside[J]; Antimicrob Chemother, 1990, 25(4): 679-687.
  • 10Rybak M J, Lomaestro BM, Rotschafer JC, et al. Vancomycin therapeutic guidelines: a summary of consensus recommendations from the Infectious Diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists[J]. Clin Infect Dis, 2009, 49(3): 325-327.

共引文献829

同被引文献29

引证文献2

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部